Brief: Lipocine Doses First Patient in Phase 3 Trial for LPCN 1154 in Postpartum Depression
26/06/2025 13:03
June 26 (Reuters) - Lipocine Inc LPCN.O: LIPOCINE ANNOUNCES FIRST PATIENT DOSED IN PHASE 3 CLINICAL TRIAL FOR LPCN 1154 IN POSTPARTUM DEPRESSION LIPOCINE INC - PHASE 3 TOP LINE RESULTS EXPECTED Q2 2026 Source text: ID:nPn2hvB5Ka Further company coverage: LPCN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lipocine
See all newsUS STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
U.S. STOCKS ON THE MOVE-Hecla Mining, XPO, Lipocine
Lipocine surges after Canada approves co's testosterone replacement therapy
Brief: Lipocine Announces Health Canada Approval Of Tlando For Testosterone Replacement Therapy